Global Benign Prostatic Hyperplasia Devices Market Size By Type (Transurethral Resection of the Prostate (TURP), Transurethral Microwave Therapy (TUMT)), By Application (Hospitals and Clinics, Ambulat...

The Global Benign Prostatic Hyperplasia (BPH) Devices Market was valued at USD 4.2 billion in 2023 and is projected to surpass USD 7.8 billion by 2031, registering a CAGR of 7.8% during the forecast period from 2023 to 2031. The market growth is primarily driven by the rising prevalence of benign prostatic hyperplasia (BPH) among the aging male population, increasing adoption of minimally invasive treatments, and technological advancements in BPH treatment devices.

Benign prostatic hyperplasia is a common condition in elderly men that leads to urinary retention, frequent urination, and other lower urinary tract symptoms (LUTS). The market for BPH devices is expanding due to a growing preference for minimally invasive surgical techniques (MISTs), which offer reduced recovery time and lower risks compared to traditional surgeries.

Market Drivers

1. Growing Geriatric Population and Rising BPH Cases

The incidence of benign prostatic hyperplasia (BPH) increases with age, affecting over 50% of men aged 50 and above and nearly 90% of men aged 80 and above. As life expectancy rises globally, the demand for effective BPH treatment solutions is increasing.

2. Advancements in Minimally Invasive Surgical Techniques (MISTs)

Technological advancements have led to the development of minimally invasive BPH treatment devices, such as:

Rezum Water Vapor Therapy

UroLift System

Prostatic Artery Embolization (PAE)

Laser-based therapies (e.g., GreenLight Laser Therapy)

These techniques provide shorter hospital stays, faster recovery times, and fewer complications, driving their adoption.

3. Increasing Awareness and Favorable Reimbursement Policies

Growing patient awareness regarding effective, non-invasive treatments and the availability of medical reimbursement schemes in developed countries are encouraging more individuals to seek BPH treatment.

Market Restraints

1. High Cost of BPH Treatment Devices

The cost of advanced BPH treatment devices and minimally invasive procedures remains high, limiting their affordability, especially in low-income and developing regions.

2. Limited Awareness in Emerging Economies

Despite rising awareness in developed countries, lack of awareness and healthcare accessibility in emerging markets can slow market growth.

Market Opportunities

1. Growth in Emerging Markets

Developing nations, particularly in Asia-Pacific, Latin America, and the Middle East, present untapped growth potential. Increasing healthcare expenditures, rising patient awareness, and expanding medical infrastructure are expected to boost the adoption of BPH devices.

2. Expanding Adoption of Laser-Based Therapies

GreenLight laser therapy, holmium laser enucleation (HoLEP), and thulium laser technologies are becoming increasingly popular due to their effectiveness in reducing prostate size with minimal side effects.

Market Segmentation Insights

Market by System Type

Laser-Based BPH Devices – Dominated the market in 2023 due to their effectiveness in precise prostate tissue removal with minimal bleeding.

Implant-Based BPH Devices (e.g., UroLift) – Expected to witness significant growth owing to their ability to provide long-term relief from BPH symptoms without cutting or removing prostate tissue.

Radiofrequency Ablation Devices – Gaining popularity for thermal destruction of prostate tissue, reducing urinary symptoms.

Transurethral Microwave Therapy (TUMT) Devices – Used for heating and reducing prostate tissue to improve urine flow.

Market by End-Use

Hospitals – Held the largest market share in 2023 due to high patient footfall, availability of advanced treatment options, and skilled healthcare professionals.

Ambulatory Surgical Centers (ASCs) – Expected to grow rapidly, driven by cost-effective procedures and shorter recovery periods.

Specialty Clinics & Urology Centers – Witnessing increased adoption of minimally invasive treatments for outpatient procedures.

Market by Regional Insights

North America – Dominated the global BPH devices market in 2023 due to high awareness levels, favorable reimbursement policies, and strong healthcare infrastructure.

Europe – The second-largest market, led by Germany, France, and the UK, with rising demand for laser-based BPH treatments.

Asia-Pacific – Expected to witness the fastest growth, fueled by rapidly aging populations in Japan, China, and South Korea, along with increasing healthcare investments.

Latin America & Middle East & Africa – Growing medical tourism and improving healthcare accessibility are driving market expansion in these regions.

Competitive Landscape

Key players in the Global BPH Devices Market include:

Boston Scientific Corporation

Teleflex Incorporated

Lumenis Ltd.

Urologix LLC

KARL STORZ SE & Co. KG

Olympus Corporation

NeoTract, Inc. (a subsidiary of Teleflex)

Medtronic plc

Procept BioRobotics Corporation

Key Market Developments

2023: Boston Scientific launched an advanced Rezum Water Vapor Therapy system, offering improved outcomes in BPH symptom relief.

2023: Teleflex Incorporated expanded its UroLift System portfolio, targeting global expansion in emerging markets.

2024: Medtronic introduced robot-assisted BPH surgery technology, enhancing precision and efficiency in minimally invasive treatments.

Scope of Work – Global Benign Prostatic Hyperplasia (BPH) Devices Market

Report Metric Details

Market Size (2023) USD 4.2 billion

Projected Market Size (2031) USD 7.8 billion

CAGR (2023-2031) 7.8%

Key Segments by System Type Laser-Based BPH Devices, Implant-Based BPH Devices, Radiofrequency Ablation Devices, Transurethral Microwave Therapy (TUMT) Devices

Key Segments by End-Use Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics & Urology Centers

Leading Region North America

Key Players Boston Scientific, Teleflex, Lumenis, Olympus, Medtronic, NeoTract, Urologix

Frequently Asked Questions (FAQs)

1. What is the current market size of the Global BPH Devices Market?

The Global Benign Prostatic Hyperplasia (BPH) Devices Market was valued at USD 4.2 billion in 2023.

2. What is the major growth driver of the BPH Devices Market?

The major driver is the increasing geriatric population and rising prevalence of BPH, along with technological advancements in minimally invasive treatments.

3. Which region is expected to hold the largest market share during the forecast period?

North America is expected to dominate the market due to high adoption rates of advanced BPH devices and strong healthcare infrastructure.

4. Which segment accounted for the largest market share in the BPH Devices Market?

The Laser-Based BPH Devices segment led the market in 2023, driven by high precision, minimal invasiveness, and improved patient outcomes.

5. Who are the key players in the BPH Devices Market?

Leading companies in the market include Boston Scientific, Teleflex, Medtronic, Lumenis, Olympus, and NeoTract.

This report provides comprehensive insights into the Global Benign Prostatic Hyperplasia (BPH) Devices Market, covering market trends, key drivers, restraints, opportunities, segmentation, regional analysis, competitive landscape, and future outlook.